# US 2014/0194405 A1 · Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194405 A1
- Document ID: US20140194405A1
- Status: Published application
- Kind: A1
- Application number: 14/136,295
- Filed: 2013-12-20
- Published: 2014-07-10
- Earliest claimed: 2010-04-29
- Assignees: Deciphera Pharmaceuticals, LLC
- Applicants: Deciphera Pharmaceuticals, LLC
- Inventors: Daniel L. Flynn; Michael D. Kaufman
- Web page: https://patentgrep.com/patent/US20140194405A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 239/47: One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed: or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.

## Claims

### Claim 1

A compound of Formula I,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof,
wherein
X is halogen;
Z1 and Z2 are independently CR2 or N;
Z3 is CH or N;
and wherein one or two of Z1, Z2 and Z3 is N;
each R1 is independently and individually halogen, H, C1-C6 alkyl branched C3-C7 alkyl, C3-C7 cycloalkyl, or —CN;
each R2 is individually and independently H, halogen, C1-C6 alkyl or cyano;
R3 is —C(O)R4, —C(O)—C6-C10-aryl, —C(O)—C4-C6-heterocyclyl, or —C(O)—C5-C6-heteroaryl, wherein
aryl is phenyl naphthyl, tetrahydronaphthyl, indenyl or indanyl; and
with the proviso that when R3 is —C(O)—C4-C6-heterocyclyl, the heterocyclyl does not have a N bonding hand to —C(O);
R4 is C3-C8 cycloalkyl, C1-C7 alkyl, —(CH2)p—CN, —(CH2)p—OR6, —(CH2)p—NR6(R7), —(CH2)p—SO2—C1-C6-alkyl, —(CH2)p—C6-C10-aryl, —(CH2)p—C5-C6-heteroaryl, or —(CH2)p—C4-C6-heterocyclyl, wherein
each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl; and
aryl is phenyl, naphthyl, tetrahydronaphthyl, indenyl or indanyl;
each R6 and R7 is individually and independently H, C1-C6 alkyl, or C3-C8 branched alkyl;
each cycloalkyl, aryl, heteroaryl and heterocyclyl is independently substituted with -(R25)m;
each R25 is individually and independently C1-C6 alkyl, branched C3-C8 alkyl, halogen, —(CH2)m—CN, —(CH2)m—OR6, —(CH2)m—NR6(R7), —(CH2)m—SO2—C1-C6-alkyl, —(CH2)m—C(O)NR6(R7), —(CH2)m—C(O)—C4-C6-heterocyclyl, or —(CH2)m—C4-C6-heterocyclyl, wherein each alkyl or alkylene is optionally substituted with one or two C1-C6 alkyl;
each m is individually and independently 0, 1, 2, or 3; and
p is 1, 2, or 3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula If,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof, and
wherein
n is 0, 1, or 2.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R3 is —C(O)R4.

### Claim 4 (depends on 2)

The compound of claim 2, wherein R3 is —C(O)—C6-C10-aryl, —C(O)—C4-C6-heterocyclyl, or —C(O)—C5-C6-heteroaryl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Ij,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, or tautomer thereof.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R3 is —C(O)R4.

### Claim 7 (depends on 5)

The compound of claim 5, wherein R3 is —C(O)—C6-C10-aryl, —C(O)—C4-C6-heterocyclyl, or —C(O)—C5-C6-heteroaryl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound of formula I is N-(4-(2-acetamidopyrimidin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.

### Claim 9 (depends on 1)

A method of treating mammalian disease wherein the disease etiology or progression is at least partially mediated by a kinase activity, wherein the kinase is a wildtype form, a mutant oncogenic form, an aberrant fusion protein form or a polymorph, the method comprising administering to a mammal in need thereof an effective amount of a compound of claims 1.

### Claim 10 (depends on 9)

The method of claim 9, wherein the disease etiology or progression is at least partially mediated by the kinase activity of c-MET, mutant oncogenic forms, aberrant fusion proteins, or polymorphs thereof.

### Claim 11 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The composition of claim 11, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

### Claim 13 (depends on 1)

A method of treating cancer, gastrointestinal stromal tumors, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, or diseases characterized by angiogenesis, such as solid tumors, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including retinopathies, diabetic retinopathy, age-related macular degeneration, hypereosinophilic syndrome, rheumatoid arthritis, asthma, chronic obstructive pulmonary, mastocytosis, or mast cell leukemia, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the compound is administered orally, parenterally by inhalation, or subcutaneously.

### Claim 15 (depends on 2)

A pharmaceutical composition, comprising the compound of claim 2 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The composition of claim 15, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

### Claim 17 (depends on 5)

A pharmaceutical composition, comprising the compound of claim 5 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The composition of claim 17, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

### Claim 19

A pharmaceutical composition comprising the compound N-(4-(2-acetamidopyrimidin-4-yloxy)-2,5-difluorophenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, or a pharmaceutically acceptable salt, thereof and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 19)

The composition of claim 19, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.
